Skip to main
GKOS
GKOS logo

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 20%
Hold 20%
Sell 5%
Strong Sell 0%

Bulls say

Glaukos Corporation has demonstrated a notable improvement in its financial performance, highlighted by an operating margin increase of 2,200 basis points year-over-year, reaching (17.3%), surpassing consensus expectations of (21.6%). The company has successfully grown its iDose revenue to approximately $16 million and is projecting a sales contribution of about $115-120 million by 2025, reflecting strong demand for its innovative products. Additionally, Glaukos’ glaucoma revenue reached $84 million, exceeding expectations and showing a remarkable 39% growth, indicating robust market momentum and the potential for substantial revenue expansion through upcoming product launches and a promising pipeline.

Bears say

The analysis of Glaukos Corp reveals a concerning decline in financial performance, particularly with a miss in Corneal Health revenue, which totaled $21 million against a consensus of $22 million, reflecting a growth slowdown from the previous quarter. Additionally, the company's gross margin decreased to 82.3%, slightly below consensus expectations, alongside a relatively high SG&A ratio of 65.0% that may indicate inefficiencies. Management's forecast for flat to declining US iStent franchise revenue amidst rising competition and operational risks raises significant doubts about future growth potential and profitability.

Glaukos (GKOS) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 20 analysts, Glaukos (GKOS) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.